In 2016, Moderna partnered with United VARs member, Answerthink, to build an integrated finance and supply chain system. Phase 1 included a full finance and procurement system based on S/4 HANA, LMS, Concur, SuccessFactors, and Business Objects. In 2020, Moderna developed their COVID-19 Vaccine, which led to unprecedented growth due to the pandemic. They went from pre-commercial biotech to sales of $28+Billion in one year.
“It was very clear to me from day one that infusing digitalization from the ground up was not only an opportunity but a requirement for our company to succeed.” - Stéphane Bancel, Founding CEO at Moderna.
With the World Health Organization recommending the use of messenger RNA (mRNA) vaccine, Moderna needed to:
Quickly mobilize its global supply chains.
Comply with international legislation aimed at preventing counterfeit medicines.
Scale faster and take advantage of digital technologies to support global serialization and distribution.
“Integrating product serialization and secure distribution technologies into Moderna’s digital landscape with SAP solutions allows us to deliver the millions of vaccines we need to produce and distribute safely.” - Marcello Damiani, Chief Digital Officer at Moderna.
The SAP / Answerthink team was able to sell the long-term vision of the SAP partnership, versus point solutions, affirming the benefits by the numbers. Moderna invested in technology supporting the vision for an intelligent enterprise, having undergone a full-scale digital transformation using SAP S/4HANA, Ariba, Fieldglass portfolio, and Concur solutions. This SAP environment met country-specific requirements and complied with international and regional legislation.
“SAP and Answerthink were able to combine our expertise in life science to help Moderna build their S/4HANA centric intelligent enterprise while supporting their rapid global expansion and meeting all the regulatory compliance requirements.” - John McGrath, Principal & Managing Director at Answerthink.
In his LinkedIn article, Christian Klein, CEO & Member of the Executive Board of SAP wrote that “Never before have scientists and pharmaceutical companies focused so intently on the development of a vaccine both with manpower and money. Never before was the urge to deliver more pressing. And never before was our chance to truly help the world run better and improve people’s lives greater. In these times, Intelligent Enterprises can make a difference. The development of a new vaccine within just one year is an unbelievable accomplishment, and we at SAP are ready to help deliver it to all parts of the world.”
www.united-vars.com
